How Sandoz turned a 14-amino-acid hormone into an 8-amino-acid drug — the story of octreotide
Somatostatin inhibits the release of growth hormone, insulin, glucagon and many digestive hormones in the body. It was not clinically usable: half-life below three minutes. In the 1970s a Sandoz research group in Basel cut the 14-amino-acid peptide down to eight amino acids, kept the critical β-turn — and had the first somatostatin analog with clinical half-life on the market in 1988.
Somatostatin: a hormone with too short a breath
In 1973 Roger Guillemin at the Salk Institute isolated from sheep hypothalamus a 14-amino-acid peptide with the unexpected property of inhibiting growth hormone secretion. He called it somatostatin — literally 'growth-standing-still'. Later work showed that the same peptide also inhibits glucagon, insulin, TSH and a series of gastrointestinal hormones such as gastrin, secretin and cholecystokinin. The clinical interest was immediate: there were medical situations — acromegaly (pathological growth hormone excess), hormone-producing tumours of the digestive tract (carcinoid syndrome, VIPomas, glucagonomas) — in which a universal hormone inhibitor would be therapeutically valuable.
The pharmacokinetic problem was fatal: native somatostatin has a plasma half-life of about 1-3 minutes because it is rapidly degraded by endo- and exopeptidases. A continuous infusion via a central line was feasible in hospital but ruled out for ambulatory therapy. The substance needed a stabilised analog.
Sandoz, Basel: from hormone to medicine
In the late 1970s a chemically ambitious project started at Sandoz Pharma in Basel under Wilfried Bauer. The central hypothesis: the biological activity of somatostatin lies not in the entire 14-amino-acid sequence but in the β-turn between amino acids 7-10 (Phe-Trp-Lys-Thr). If this turn is stabilised by cyclic disulphide bonding and the enzymatically labile residues are replaced by D-amino acids, a substantially shorter, substantially more stable analog should emerge — with similar receptor affinity.
The result was SMS 201-995, later known as octreotide: a cyclic octapeptide (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol) with a plasma half-life of about 90-120 minutes on subcutaneous administration — roughly 30-fold longer than native somatostatin. The substance is receptor-selective: high affinity for somatostatin receptor SSTR2 and SSTR5, lower for SSTR1/3/4 — yielding a more favourable side-effect profile than the native hormone.
Acromegaly and carcinoid syndrome
Clinical development started in the early 1980s. In Rotterdam under Janet Lamberts and at several European centres octreotide was used in acromegaly — the condition in which a mostly benign pituitary tumour produces excessive growth hormone. In a significant proportion of patients, octreotide led to normalisation of IGF-1 levels and clinical symptom improvement. A second central indication was carcinoid syndrome — neuroendocrine tumours of the gastrointestinal tract that excessively release serotonin and other vasoactive substances and thus cause flushing, diarrhoea and cardiac damage. Octreotide effectively controlled these symptoms.
In 1988 octreotide received FDA approval under the name Sandostatin for acromegaly and carcinoid syndrome. It was the first somatostatin analog on the market — and one of the first approved peptide therapies at all that did not replicate a directly body-identical hormone (like insulin) but were a deliberately modified design peptide.
„We reduced the active by six amino acids and extended half-life 30-fold. That is the typical equation of 1980s medical peptide chemistry — and it was the foundation for a whole substance class."
The iteration: depot and generations
Octreotide initially required three to four subcutaneous injections per day. In 1998 Sandostatin LAR (Long-Acting Release) was approved — a depot microsphere formulation administered intramuscularly once per month. This made acromegaly and carcinoid therapy ambulatorily practical.
Further somatostatin analogs with different receptor-affinity profiles followed: lanreotide (Ipsen, 1995 EU approval) — structurally related, also as monthly depot. Pasireotide (Novartis, 2012) — broader SSTR affinity profile (SSTR1/2/3/5), approved for Cushing's syndrome and hard-to-treat acromegaly. Octreotide-LAR and lanreotide depot are today among the standard therapies for neuroendocrine tumours. With the market launch of Lutathera (177Lu-DOTATATE, 2018), somatostatin analogs were additionally used as a radioactive tumour-targeting platform for peptide receptor radionuclide therapy.
What the octreotide story methodologically shows
Three structural observations are valuable from this line. First: rational peptide reduction — from the 14-mer to the 8-mer with preserved activity — is a reproducible strategy successfully applied to many hormone analogs (GnRH, GHRH, calcitonin, insulin) in the 1980s and 1990s. Second: half-life extension by an order of magnitude was often more decisive than a theoretical potency increase — a lesson that recurred decades later in the GLP-1 story (exenatide → liraglutide → semaglutide). Third: a peptide can found a therapeutic class without being 'life-saving' in the insulin sense — octreotide did not turn a lethal disease into a chronic one, but made a rare neuroendocrine disease group substantially more treatable.
Open questions
- How far can rational reduction be pushed with other hormones — when does a peptide lose its critical conformation with increasing shortening?
- Which neuroendocrine tumours respond worse to octreotide/lanreotide — and which new SSTR-subtype-specific ligands address this resistance?
- How are global therapy costs changing now that generics for the standard octreotide formulation are available but depot forms remain patent-protected?
- What role will peptide receptor radionuclide therapy (PRRT) play in future oncology of small tumours — beyond NETs?